RMC
Indication: ALK-positive or ROS1-positive non-small cell lung cancer
PK/PD simulator for lorlatinib, an oral ALK/ROS1 tyrosine kinase inhibitor used in advanced NSCLC. Includes oral PK, ALK phosphorylation rebound, and tumor growth inhibition components based on preclinical translational modeling.
Drug Overview
Clinical Context
- Molecular Target
- ALK and ROS1
- Drug Class
- ALK/ROS1 Tyrosine Kinase Inhibitor
- Therapeutic Area
- Oncology / NSCLC
- Indication
- ALK-positive or ROS1-positive non-small cell lung cancer
- Route of Administration
- Oral
Model Information
- Model Type
- Population PK/PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for RMC allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK/PD model characterizes the pharmacokinetics of this alk/ros1 tyrosine kinase inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the RMC PK simulator?
This is a free, interactive pharmacokinetic simulator for RMC used in ALK-positive or ROS1-positive non-small cell lung cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does RMC belong to?
RMC is classified as a ALK/ROS1 Tyrosine Kinase Inhibitor that targets ALK and ROS1. It is used in the Oncology / NSCLC therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of RMC. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the RMC simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community